The estimated Net Worth of Alan Seth Krasner is at least $4.09 Milión dollars as of 17 October 2023. Alan Krasner owns over 7,000 units of Crinetics Pharmaceuticals Inc stock worth over $2,547,655 and over the last 6 years he sold CRNX stock worth over $0. In addition, he makes $1,545,780 as Chief Medical Officer at Crinetics Pharmaceuticals Inc.
Sign up
Alan Krasner CRNX stock SEC Form 4 insiders trading
Alan has made over 3 trades of the Crinetics Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of CRNX stock worth $84,070 on 17 October 2023.
The largest trade he's ever made was exercising 7,000 units of Crinetics Pharmaceuticals Inc stock on 17 October 2023 worth over $84,070. On average, Alan trades about 1,744 units every 213 days since 2018. As of 17 October 2023 he still owns at least 50,210 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Alan Krasner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alan Krasner biography
Dr. Alan Seth Krasner M.D. serves as Chief Medical Officer of the Company. Dr. Krasner served as Global Clinical Development Lead at Shire plc, a global biotechnology company focused on the treatment of rare diseases. Before joining Shire, Dr. Krasner served from May 2008 to November 2015 as Chief Medical Officer for Biodel Inc., a specialty biopharmaceutical company focused on the treatment of diabetes. Prior to Biodel, from 2002 to 2008, Dr. Krasner served as Director in the Department of Clinical Research Metabolic Diseases at Pfizer Global Research and Development, where he was responsible for the design, execution, clinical analysis, and reporting of multiple, global clinical trials supporting registration of late stage drug candidates. Dr. Krasner served as a consulting physician at the Joslin Diabetes and Endocrinology Center of the Lawrence and Memorial Hospital in New London, Connecticut until July 2017. Dr. Krasner holds a B.S. from the Medical Education Honors Program at Northwestern University and a M.D. from Northwestern University Medical School. He completed his residency at Johns Hopkins Hospital in internal medicine and subsequently completed his fellowship at Johns Hopkins Hospital in endocrinology and metabolism.
What is the salary of Alan Krasner?
As the Chief Medical Officer of Crinetics Pharmaceuticals Inc, the total compensation of Alan Krasner at Crinetics Pharmaceuticals Inc is $1,545,780. There are 1 executives at Crinetics Pharmaceuticals Inc getting paid more, with R. Scott Struthers having the highest compensation of $3,766,660.
How old is Alan Krasner?
Alan Krasner is 56, he's been the Chief Medical Officer of Crinetics Pharmaceuticals Inc since 2018. There are 9 older and 9 younger executives at Crinetics Pharmaceuticals Inc. The oldest executive at Crinetics Pharmaceuticals Inc is Wendall Wierenga, 72, who is the Independent Chairman of the Board.
What's Alan Krasner's mailing address?
Alan's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG 2, SAN DIEGO, CA, 92121.
Insiders trading at Crinetics Pharmaceuticals Inc
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen a Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
What does Crinetics Pharmaceuticals Inc do?
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
What does Crinetics Pharmaceuticals Inc's logo look like?
Complete history of Alan Krasner stock trades at Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc executives and stock owners
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
R. Scott Struthers,
President, Chief Executive Officer, Director -
Alan Krasner,
Chief Medical Officer -
Marc Wilson,
Chief Financial Officer -
Dr. R. Scott Struthers Ph.D.,
Founder, Pres, CEO & Director -
Dr. Ajay Madan DABT, Ph.D., D.A.B.T.,
Chief Devel. Officer -
Marc J. C. Wilson,
CFO & Sec. -
Stephanie Okey,
Independent Director -
Wendall Wierenga,
Independent Chairman of the Board -
Matthew Fust,
Independent Director -
Jeff E. Knight,
Chief Operating Officer -
Stephen Kaldor,
Independent Director -
Weston Nichols,
Independent Director -
Peter Trainer,
Vice President - Clinical Endocrinology -
Camille Bedrosian,
Independent Director -
Adriana Cabre,
Vice President of Human Resources -
Ajay Madan,
Chief Development Officer -
Chris Robillard M.B.A.,
Chief Bus. Officer -
James Hassard,
Chief Commercial Officer -
Dr. Alan S. Krasner M.D.,
Chief Medical Officer -
Adriana Cabre M.B.A.,
Chief HR Officer -
Kevin Capps,
Head of Intellectual Property -
Dr. Alan S. Krasner,
Chief Medical Officer -
Garlan Adams,
Gen. Counsel -
Dr. Stephen F. Betz Ph.D.,
Founder & Chief Scientific Officer -
Dr. Yun-Fei Zhu,
Founder & VP of Chemistry -
Jeff E. Knight,
Chief Operating Officer -
Advisors Llcperceptive Life...,
-
Capital Viii, Llc Vivo Capi...,
-
Venture Capital V, L.P.Vers...,
-
Capital Viii, Llc Vivo Capi...,
-
Venture Capital V, L.P.Vers...,
-
Capital Viii, Llc Vivo Capi...,
-
James Hassard,
Chief Commercial Officer -
Jack Nielsen,
Director -
Coelho Rogerio Vivaldi,
-
Dana Pizzuti,
Chief Med and Dev Officer -
Stephen F. Betz,
Chief Scientific Officer -
Caren Deardorf,